Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.
Cisplatin Induced Hearing Loss
DRUG: OTO-104
Feasibility assessed via a questionnaire, Feasibility to assess incorporating OTO-104 with a cisplatin-based therapy regimen, Up to 18 weeks
Hearing function in each ear according to SIOP-Boston Ototoxicity Scale, Up to 6 months|Safety as assessed by adverse events, Up to 6 months|Local tolerability as assessed by otoscopic examinations, Up to 6 months
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.